• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The present invention relates to the stabilization of vaccine compositions held in a liquid state by the use of high molecular weight polyvinylpyrrolidone, whereby the use of albumin is excluded. The present invention relates in particular to vaccine compositions comprising directed live viruses, such as vaccines for oral polio.
    公开号:KR20030096223A
    申请号:KR10-2003-7004927
    申请日:2001-10-08
    公开日:2003-12-24
    发明作者:프랑콘알랭；노엘캐서린
    申请人:아벤티스 파스퇴르；
    IPC主号:
    专利说明:

    Vaccine composition and stabilization method {VACCINE COMPOSITION AND STABILISATION METHOD}
    [2] One of the major problems in the field of vaccines is their stability, ie the preservation of efficacy over time. One of the proposed solutions to solve the stability problem is lyophilization. This solution is satisfactory from a technical point of view, but nevertheless has disadvantages. This drawback means, on the one hand, an additional step of increasing manufacturing costs and duration in the case of entrepreneurs, and on the other hand involves the task of melting the lyophilized product prior to product administration.
    [3] Another solution proposed by the prior art to preserve the efficacy of the vaccine over time is to use a stabilizing formulation that generally comprises albumin. However, the very high cost associated with the use of recombinant albumin, as well as the contamination risk present with albumin of human or animal origin, has led to the search for albumin substitutes to stabilize liquid vaccines.
    [4] Replacement of the albumin has already been attempted in other pharmaceutical applications. Thus, US Pat. No. 3915794 proposes the replacement of animal proteins such as albumin or casein with low molecular weight polyvinylpyrrolidone (PVP) not only during the period of virus extraction from cells but also during subsequent lyophilization steps. Doing. However, products that can replace albumin are not always available for some of their functions, and therefore cannot be considered as universal albumin substitutes.
    [5] Thus stabilization tests of liquid vaccines over time performed using the low molecular weight PVP disclosed in the aforementioned US patents did not produce satisfactory results.
    [6] Summary of the Invention
    [7] There is therefore a need for albumin-free formulations that can stabilize liquid vaccine compositions, especially compositions comprising viruses and particularly directed live viruses.
    [8] In order to achieve the above object, the present invention proposes a method of stabilizing a vaccine composition in a liquid state by adding a high molecular weight polyvinylpyrrolidone to the vaccine composition.
    [9] Subject of the invention is also a liquid vaccine composition that is stable over time, characterized in that it comprises at least one viral antigen and at least high molecular weight polyvinylpyrrolidone.
    [10] According to a feature of the invention, the molecular weight of said PVP is at least 100,000 Daltons.
    [11] According to another feature of the invention, the PVP is used at a concentration of at least 0.1% by weight and preferably less than 5% by weight.
    [12] According to another feature of the invention, said vaccine composition comprises supervised live virus. It may be a vaccine composition against polio, especially for oral administration.
    [13] According to another feature of the invention, the vaccine composition also comprises at least one or more surfactants as well as salts or sugars. The stability results obtained under these conditions are particularly satisfactory.
    [14] Other features of the present invention will be apparent from the following detailed description.
    [1] The present invention relates to the field of vaccines. More particularly, the present invention relates to the stabilization of liquid vaccines.
    [15] Vaccine compositions which must be provided with stability over time are vaccine compositions comprising at least one antigen consisting of a virus. The stability of such compositions is due to the preservation of the infectivity of the vaccine composition over time according to criteria defined by various regulatory authorities, which means that the virus used as an antigen must preserve the ability to infect cells. Is evaluated.
    [16] Among the vaccine compositions that can be used according to the method of the invention, mention may be made of vaccines comprising supervised live viruses and in particular vaccines against polio. It is a monovalent vaccine composition, i.e. a composition for the purpose of protection against a single disease (although the composition may comprise the same number of types, for example in the case of polio and dengue fever), or multivalent composition, ie It may comprise a vaccine for the purpose of protection against a number of diseases, wherein one or more of these numbers consists of a live virus supervised as described above.
    [17] The method according to the invention has shown the greatest value in the stabilization of oral vaccines against polio, wherein the vaccine is a supervised live viral vaccine comprising three types of poliovirus.
    [18] According to the invention, the vaccine composition is stabilized by the addition of high molecular weight polyvinylpyrrolidone (or PVP), in particular PVP360 having an MW of 360,000 Daltons. Indeed, against all expectations, the low molecular weight PVPs disclosed in the prior art as stabilizing factors during the extraction step of the virus as well as during the freeze drying step and the storage of the lyophilized product could not satisfactorily stabilize the vaccine composition in the liquid state. It has been found that the high molecular weight PVP can very advantageously replace albumin commonly used in stabilizing formulations of liquid vaccine compositions. The excellent properties of the results obtained are even more surprising when considering the teaching of US Pat. No. 3915794, as PVP K90 with a MW of 360,000 is not satisfactory for stabilization of the virus suspension.
    [19] PVP is a synthetic chemical product; Its origin is not critical with respect to the present invention, provided that it has pharmaceutically acceptable properties. Thus, PVP360 provided by Sigma is very suitable for use in accordance with the present invention.
    [20] The concentration of PVP is at least 0.1% weight / volume. However, it is preferable not to exceed the concentration of 5% so that there is no problem associated with the viscosity of the medium. Good results were obtained with a concentration of 1%.
    [21] Advantageously, the vaccine composition according to the invention also comprises a certain amount of surfactant, for example polyethylene glycol (or PEG). It is also possible to use twin TM 80 or polysorbate 80. The amount of surfactant used is preferably in an amount of less than 0.007% weight / volume. The amount of Tween TM 80 of 0.004% gave particularly good results.
    [22] According to one feature of the invention, the vaccine composition also comprises substantially molar concentrations of salts, for example magnesium chloride MgCl 2 ; The vaccine composition may also include sugars such as glucose and saccharose, which can vary the concentration from about 20% to about 40%; The presence of these sugars is not critical to the stabilizing effect.
    [23] The vaccine composition may also include any other ingredients conventionally used in vaccines, such as preservatives and / or adjuvants. It may particularly comprise a buffer material, such as Hepes buffer, at a concentration of about 20 mM.
    [24] The following examples illustrate certain embodiments of the invention.
    [25] Example 1
    [26] Three different types of polio virus suspensions are prepared in the following manner:
    [27] A biogenerator containing 142 th passed Vero cells in Parker 199 medium is inoculated with one of these types of polio virus. The virus culture is carried out at a temperature of about 34 ° C. After a cycle not exceeding 96 hours, cell lysis is complete and virus harvesting is performed by recovering the supernatant. The harvest was purified by filtration on a membrane with a cutoff of 100,000 and then passed over a DEAE spherodex column previously equilibrated to pH 7 in 40 mM phosphate buffer. Under these conditions, viruses pass freely through the column while impurities are retained by the column.
    [28] The virus suspension passing through the column is then filtered through a membrane with a cutoff of 10,000, followed by zone ultracentrifugation with a saccharose gradient; Fractions of interest are those present at 45-55% saccharose.
    [29] A monovalent suspension of polio virus of a given type (I, II or III) is obtained as above.
    [30] Example 2
    [31] Vaccine composition,
    [32] -I type virus suspension,
    [33] -II type virus suspension,
    [34] -III type virus suspension
    [35] Was prepared from the monovalent composition prepared in Example 1 by mixing in an amount capable of obtaining a titer of 6.3 log 10 CCID 50 / dose for each strain in a volume of 100 ml to obtain a composition having the stability to be tested therein. To one of the following mixtures:
    [36] -1% albumin, 1 M MgCl 2 , 20 mM Hepes buffer, 0.002% Tween TM 80,
    [37] PVP360, 1 M MgCl 2 , 20 mM Hepes buffer,
    [38] - various concentrations of PVP360, 1 M MgCl 2, 20 mM Hepes buffer and varying concentrations of Tween TM 80,
    [39] - various concentrations of PVP360, 20 mM Hepes buffer and Tween 80 TM and the sugar at various concentrations (as glucose and saccharose Oz),
    [40] Various concentrations of PVP10, 1 M MgCl 2 , 20 mM Hepes buffer and 0.002% Tween TM 80 or
    [41] Various concentrations of PVP40, 1 M MgCl 2 , 20 mM Hepes buffer and 0.002% Tween TM 80.
    [42] The various compositions are maintained at 37 ° C. for 5 days, ie under conditions of accelerated ripening conditions that allow to evaluate the stability of the compositions obtained.
    [43] Example 3
    [44] The stability of the prepared viral compositions is assessed by assessing the decrease in infection titer over time. The determination of infection titer is carried out by the CCID50 technique, which is carried out in the following manner:
    [45] Titration is performed in 96-well microplates.
    [46] Samples were taken in MEM medium 1 × C in calf fetal serum 2% (volume / volume) containing no polio antibody, 5.6% (volume / volume) sodium bicarbonate 4% (volume / volume) without phenol red, and penicillin-dydromycin antibiotic 400xC Dilute to -1 to -6 or -7 (as log10) to 0.2% (volume / volume) of solution. For each dilution, 50 μl are dispensed into 4 rows of 10 wells:
    [47] In the first column, 50 μl of dilution medium is added (total titration),
    [48] In the second column, 50 μl of type 2 anti-polio antisera plus type 3 anti-polio antisera diluted with MEM medium is added to neutralize type 2 and type 3 polio viruses contained in the vaccine composition (I Type titration),
    [49] In the third column, 50 μl of type 1 anti-polio antisera diluted with MEM medium plus type 3 anti-polio antisera is added to neutralize type 1 and type 3 polio viruses contained in the vaccine composition (II Type titration),
    [50] In the fourth column, 50 μl of type 1 anti-poliolytic antiserum diluted with MEM medium plus type 2 anti-poliovirus antiserum is added to neutralize type 1 and type 2 poliovirus contained in the vaccine composition (III Type titration).
    [51] The eight wells of the final column of each plate serve as control cells; Add 100 μl of MEM medium per well.
    [52] Covering the plates with a cover; Shake from side to side and contact the medium at 37 ° C. for 1 hour.
    [53] After this contact time, 100 μl of HepII cell suspension is added to each well at 50,000 cells / ml. The plates are left for 9 days in the incubator at 36 ° C.
    [54] To prepare a cell suspension, the procedure should be carried out in the following manner: Cells are dissociated by the action of trypsin, counted and the cell suspension is diluted so that a concentration of 50,000 cells / ml is obtained.
    [55] After examining the integrity of the control cells, the pathogenic effect is read for each well.
    [56] After converting the data to the arc sine of the square root of the positive well portion, titers are calculated using first order regression for various dilution rates.
    [57] Assays are performed after 5 days at T0 and 37 ° C. for each virus composition prepared.
    [58] The results obtained are shown as the difference between the titer at TO and the titer after 5 days of accelerated ripening at 37 ° C. and summarized in the table below; These results are considered satisfactory when they are substantially equal to or less than the values obtained using the vaccine compositions of the prior art, ie compositions stabilized with 1% albumin.
    [59] Type 1Type 2Type 3all Albumin 1% + MgCl 2 + Hepes + Tween 0.002%0.820.670.670.67 PVP360 1% + MgCl 2 + Hepes0.060.220.070.17 PVP360 1% + MgCl 2 + Hepes + Twin 0.002%0.850.750.850.85 PVP360 2% + MgCl 2 + Hepes + Tween 0.002%1.000.850.600.75 PVP360 5% + MgCl 2 + Hepes + Tween 0.002%1.130.671.221.43 PVP360 10% + MgCl 2 + Hepes + Tween 0.002%1.801.501.651.65 PVP360 0.1% + MgCl 2 + Hepes + Tween 0.004%1.201.450.901.20 PVP360 0.5% + MgCl 2 + Hepes + Tween 0.004%0.600.700.550.75 PVP360 1% + MgCl 2 + Hepes + Tween 0.004%0.720.590.870.68 PVP360 1.5% + MgCl 2 + Hepes + Twin 0.004%0.900.550.850.85 PVP360 2.5% + MgCl 2 + Hepes + Tween 0.004%0.821.050.950.53 PVP360 4.9% + MgCl 2 + Hepes + Tween 0.004%1.000.851.250.75 PVP360 1% + MgCl 2 + Hepes + Tween 0.006%0.850.550.850.65 PVP360 2% + MgCl 2 + Hepes + Tween 0.006%0.500.701.000.45 PVP360 1.3% + MgCl 2 + Hepes + Tween 0.007%0.850.801.000.80 PVP360 3.7% + MgCl 2 + Hepes + Twin 0.007%1.050.701.250.80 PVP360 2.5% + Hepes + Twin 0.002% + Glucose 20% + Saccharose 40%1.451.200.951.20 PVP360 1.25% + Hepes + Twin 0.002% + Glucose 30% + Saccharose 40%1.351.100.801.05 PVP360 1.25% + Hepes + Twin 0.002% + Glucose 20% + Saccharose 28%1.000.850.400.95 PVP10 5% + MgCl 2 + Hepes + Tween 0.002%2.152.102.002.30 PVP10 10% + MgCl 2 + Hepes + Tween 0.002%2.102.452.102.15
    [60] PVP10 30% + MgCl 2 + Hepes + Tween 0.002%2.652.852.553.10 PVP40 5% + MgCl 2 + Hepes + Twin 0.002%Titer <3.50 after accelerated ripening3.55 PVP40 10% + MgCl 2 + Hepes + Tween 0.002%Titer <3.50 after accelerated aging test PVP40 30% + MgCl 2 + Hepes + Twin 0.002%
    权利要求:
    Claims (10)
    [1" claim-type="Currently amended] A high molecular weight polyvinylpyrrolidone is added to the vaccine composition in the liquid state.
    [2" claim-type="Currently amended] The method of claim 1 wherein the molecular weight is 100,000 or greater.
    [3" claim-type="Currently amended] The method of claim 1 or 2, wherein the concentration of polyvinylpyrrolidone is at least 0.1% or more.
    [4" claim-type="Currently amended] The method according to any one of claims 1 to 3, wherein the concentration of polyvinylpyrrolidone is 5% or less.
    [5" claim-type="Currently amended] The method of any one of claims 1 to 4, further comprising adding magnesium chloride to the vaccine composition in substantially molar concentrations.
    [6" claim-type="Currently amended] 6. The method of any one of claims 1 to 5, further comprising adding at least one or more surfactants to the vaccine composition at a concentration of no greater than 0.007%.
    [7" claim-type="Currently amended] 7. The method of any one of claims 1 to 6, wherein the polysorbate 80 is added to the vaccine composition at a concentration of 0.004%.
    [8" claim-type="Currently amended] 8. The method of any one of claims 1 to 7, wherein the vaccine composition comprises at least one antigen consisting of directed live virus.
    [9" claim-type="Currently amended] 9. The method of any one of claims 1 to 8, wherein the vaccine composition comprises three polioviruses.
    [10" claim-type="Currently amended] A liquid vaccine composition stable over time, characterized in that it comprises at least one or more viral antigens and at least high molecular weight polyvinylpyrrolidone.
    类似技术:
    公开号 | 公开日 | 专利标题
    US10525120B2|2020-01-07|Methods and compositions for live attenuated viruses
    US9314519B2|2016-04-19|Liquid stable virus vaccines
    JP4789698B2|2011-10-12|Formula for factor IX
    JP3993230B2|2007-10-17|Improved modified BRSV live vaccine
    US5763401A|1998-06-09|Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
    US8784843B2|2014-07-22|Stabilizers for freeze-dried vaccines
    EP1137758B1|2008-02-27|Method and composition for preserving adenoviruses
    EP1648485B2|2014-09-24|Formulation for a protein pharmaceutical without added human serum albumin |
    US6039958A|2000-03-21|Stabilized live vaccine
    ES2272053T3|2007-04-16|Compositions that include viruses and methods to concentrate virus preparations.
    US8617576B2|2013-12-31|Preservation of bioactive materials by freeze dried foam
    DE69736177T2|2007-05-16|Styberized erythropoietin solution with amino acids
    Thu et al.1998|The effect of temperature and humidity on dengue virus propagation in Aedes aegypti mosquitos
    Bárcena et al.2000|Horizontal transmissible protection against myxomatosis and rabbit hemorrhagic disease by using a recombinant myxoma virus
    JP4879104B2|2012-02-22|Highly concentrated, lyophilized, and liquid, factor IX formulation
    US7931919B2|2011-04-26|Method of producing glycine-stabilized, lyophilized plasma
    US6451256B1|2002-09-17|Method for preserving infectious recombinant viruses, aqueous viral suspension and use as medicine
    Fisher-Hoch et al.1989|Protection of rhesus monkeys from fatal Lassa fever by vaccination with a recombinant vaccinia virus containing the Lassa virus glycoprotein gene
    US8557253B2|2013-10-15|Stabilizing excipient for inactivated whole virus vaccine
    JP5562316B2|2014-07-30|Vaccines containing attenuated pestiviruses
    KR101395064B1|2014-05-19|Lyophilized Preparation of Botulinun Toxin
    US10736840B2|2020-08-11|Thermally stable vaccine formulations and microneedles
    US8778868B2|2014-07-15|Chemically defined vaccine stabiliser
    US7135180B2|2006-11-14|Preservation of bioactive materials by freeze dried foam
    US8795683B2|2014-08-05|Vaccine formulations and uses thereof
    同族专利:
    公开号 | 公开日
    WO2002028362A3|2003-09-12|
    MXPA03002875A|2003-07-14|
    FR2814957B1|2002-12-20|
    CA2424863A1|2002-04-11|
    AU9567201A|2002-04-15|
    CN1468091A|2004-01-14|
    KR100832551B1|2008-05-26|
    AU2001295672B2|2005-08-18|
    JP2004526667A|2004-09-02|
    EP1357895A2|2003-11-05|
    CN1298387C|2007-02-07|
    BR0114350A|2004-02-17|
    WO2002028362A2|2002-04-11|
    US6982088B2|2006-01-03|
    FR2814957A1|2002-04-12|
    NZ525117A|2006-08-31|
    US20030190331A1|2003-10-09|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    法律状态:
    2000-10-06|Priority to FR00/12,805
    2000-10-06|Priority to FR0012805A
    2001-10-08|Application filed by 아벤티스 파스퇴르
    2001-10-08|Priority to PCT/FR2001/003097
    2003-12-24|Publication of KR20030096223A
    2008-05-26|Application granted
    2008-05-26|Publication of KR100832551B1
    优先权:
    申请号 | 申请日 | 专利标题
    FR00/12,805|2000-10-06|
    FR0012805A|FR2814957B1|2000-10-06|2000-10-06|Vaccine composition and stabilization method|
    PCT/FR2001/003097|WO2002028362A2|2000-10-06|2001-10-08|Vaccine composition and stabilisation method|
    [返回顶部]